Application of targeted next generation sequencing for the mutational profiling of patients with acute lymphoblastic leukemia.

ABSTRACT:

Background

Acute lymphoblastic leukemia (ALL) is the most common cancer in children, whereas it is less common in adults. Identification of cytogenetic aberrations and a small number of molecular abnormalities are still the most important risk and therapy stratification methods in clinical practice today. Next generation sequencing (NGS) technology provides a large amount of data contributing to elucidation of mutational landscape of childhood (cALL) and adult ALL (aALL).

Methods

We analyzed DNA samples from 34 cALL and aALL patients, using NGS targeted sequencing TruSeq Amplicon - Cancer Panel (TSACP) which targets mutational hotspots in 48 cancer related genes.

Results

We identified a total of 330 variants in the coding regions, out of which only 95 were potentially

SUBMITTER: Janic D 

PROVIDER: S-EPMC7290126 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature